AC IMMUNE SA
AC IMMUNE SA
Share · CH0329023102 · ACIU · A2AR5F (XNAS)
Overview Financial Indicators
1,97 USD
-4,83 % -0,10 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
13.06.2025 22:56

Current Prices from AC IMMUNE SA

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ACIU
USD
13.06.2025 22:56
1,97 USD
2,07 USD
-4,83 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % -3,85 % 25,26 % -14,53 % -33,67 % -58,35 % -71,57 %

Company Profile for AC IMMUNE SA Share

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Invested Funds

The following funds have invested in: AC IMMUNE SA invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
17,87
Percentage (%)
0,04 %

Company Data

Name AC IMMUNE SA
Company AC Immune SA
Symbol ACIU
Website https://www.acimmune.com
Primary Exchange XNAS NASDAQ
WKN A2AR5F
ISIN CH0329023102
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Andrea Pfeifer Ph.D.
Market Capitalization 147 Mio
Country Switzerland
Currency USD
Employees 0,1 T
Address Building B, 1015 Lausanne
IPO Date 2016-09-23

Ticker Symbols

Name Symbol
Frankfurt IMR.F
NASDAQ ACIU

More Shares

Investors who AC IMMUNE SA hold also have the following shares in their portfolio:
APPLE INC
APPLE INC Share
CAIXA GERAL 21/27 FLR MTN
CAIXA GERAL 21/27 FLR MTN Bond
CONTINENTAL AG
CONTINENTAL AG Share
FISKER INC CLASS A
FISKER INC CLASS A Share
HALO COLLECTIVE INC
HALO COLLECTIVE INC Share
HANETFPROCSPACE DLA
HANETFPROCSPACE DLA ETF
ISHSII-GL.WATER DLDIS
ISHSII-GL.WATER DLDIS ETF
LANDWIRT.R.BK 19/26LS-MTN
LANDWIRT.R.BK 19/26LS-MTN Bond
METRO AG
METRO AG Share
PAYPAL INC
PAYPAL INC Share
TUI AG
TUI AG Share
XIAOMI CORP CL.B
XIAOMI CORP CL.B Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025